Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2027-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase I dose-escalation study to evaluate the safety, tolerability and preliminary efficacy of an autologous BCMA-targeting RNA-engineered CAR T-cell therapy in patients with Relapsed/Refractory Multiple Myeloma. The cell product is referred to as Descartes-15